... recovered positive in ER- negative human breastcancer cell lines MDA-MB231, and protein levels of MMP-9 and CyclinD1 were down-regulation (P < 0.05) However, inER alpha-positive breastcancer ... were down-regulated(*P < 0.05) But in ERapositive breastcancer cells MCF-7, protein levels of ER alpha, MMP-9 and CyclinD1 had no distinct difference in three groups (P > 0.05) MTA1 in two breast ... gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation inbreastcancer cell lines MDA-MB-231 and MCF7 in vitro Journal of Experimental...
... Co-ordinating Group Cancer Services Co-ordinating Group 2000 22 Dewar JA, Twelves CJ, Thomson CS for the Scottish BreastCancer Focus Group and the Scottish Cancer Therapy Network BreastCancerin ... from breastcancerin England and Wales in 2000 (Table 1), breastcancer survival rates are higher than those for any other major cancerin women except endometrial cancer and have been improving ... six extra breast cancers per thousand women, increasing the individual risk over 20 years (age 50 to 70) from one in 22 to one in 19.12 Berrino F et al Survival of Cancer Patients in Europe:...
... population, in co-operation with cancer registries and clinicians, This includes cancers diagnosed outside screening (interval cancers, cancers in non attenders, cancers in women not invited) All ... screening should be established in line with the routine screening interval, taking into consideration that most programmes not succeed in keeping the routine screening interval for each individual ... 20:53 Pagina 24 EPIDEMIOLOGICAL GUIDELINES FOR QUALITY ASSURANCE INBREASTCANCER SCREENING Table 8: Mode of invitation Mode of invitation Initial screening* Invitation Reminder Interval* (yes/no)...
... known HER ligands bind directly to HER2 with high affinity, heregulin, a cytokine secreted by the breast stromal cells, can activate HER2 by inducing or stabilizing heterodimers with other HER receptors ... growth of breastcancer cells, to trigger the apoptotic signaling inbreast cancers, thus switching the estrogenic hormones from potential mitogens to apoptosis inducers inbreast cancers (Shi, ... activity in treatment of breast cancers in a phase I trial, and conferred therapeutic benefits in combination with chemotherapy in triple-negative breast cancers without an increase in normal...
... angiotensin II type 1, interleukin and C-C chemokine receptors Chemokines [27,28] and angiotensin II [29] have both shown growth-inhibiting properties with different cancers Interestingly, an ... other genes These were expressed in MPA-treated cells, but not in the control cells at either 24 or 48 h in differential display analysis Progestins upregulate GPR30 mRNA in MCF-7 breastcancer ... progestin-induced growth inhibition inbreastcancer cells Figure 2A shows that GPR30 mRNA expression correlated with cell growth as the dose of MPA increased; this further indicated progestin-dependent...
... delay in operable breastcancer patients Eur J Cancer Prev 2001, 10:53-59 Ebrahimi M, Vahdaninia M and Montazeri A: Risk factors for breastcancerin Iran: a case-control study BreastCancer Research ... patients with breastcancer presented to a doctor earlier [28] Finally, it is worth noting that there were several limitations inherent in this study and the findings cannot be generalized beyond ... diagnosed breastcancer patients who were admitted to a university hospital or attending a breast clinic in Tehran, Iran were interviewed following their surgery or first course of chemotherapy between...
... to increase We observed an increase in HIF-1a protein, and thus were confident that the cells were being maintained in a low-oxygen environment and were responsive to low oxygen There is also increasing ... or enhancer for its biological activity Finally, our experiments were performed in the presence of 1% serum, whereas other studies were performed in 10% serum With the low level of in vivo toxicity ... tissue oxygen distribution inbreast cancers by computerized O2 tension measurements Cancer Res 51, 3316–3322 Semenza GL (2003) Targeting Hif-1 for cancer therapy Nat Rev Cancer 3, 721–732 Kim M, Park...
... other hand, is expected to yield superior classification of serum protein features of a number of cancers in the near future [47] Translational research inbreastcancerBreastcancerBreastcancer ... This integrated approach should lead to a better understanding of the underlying biology of living cells and organisms, resulting in turn in a more effective translation of basic discoveries into ... Translational BreastCancer Research (DCTB), to fight breastcancer DCTB hosts scientists working in various areas of preclinical cancer research (cell cycle control, invasion and microenvironmental alterations,...
... lower incidence of breastcancer [1,2] It has also been noted that as breastcancer progresses, there is a corresponding increase in the number of leukocytes, both of lymphoid and myeloid origin, ... human breastcancer Clin Cancer Res 2000, 6:3282-3289 Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J: Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors Cancer Res 2006, ... adaptive and innate immune cells during breastcancer progression BreastCancer Res 2007, 9:212 Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and...
... expression are inversely correlated inbreastcancer either primary (p < 0.0001) or metastatic (p < 0.023), in primary non -breast tumors (p < 0,007) and inbreast tumors generated in HER-2/neu transgenic ... anticancer activity of the hTid proteins occurs through the interference with multiple oncogenic pathways by binding and modifying functions of key molecules maintaining intracellular signalling ... lesions) were characterized by positive staining ranging from moderate to intense staining In the context of the potential association of htid expression with the biology of human breast cancers of...
... measurement in randomized clinical trials inbreastcancer – taking stock Journal of the National Cancer Institute 2003, 95(4):263-281 Montazeri A: Health-related quality of life inbreastcancer patients: ... requiring hospital visits There were no age restrictions Patients were included in the trial after finalizing treatment and after giving written informed consent Treatment included surgery and/or ... M, Dehing C, Lambin P, Boersma LJ: Follow-up after curative treatment for breast cancer: why we still adhere to frequent outpatient clinic visits? Eur J Cancer 2007, 43(4):647-653 Koinberg IL,...
... known HER ligands bind directly to HER2 with high affinity, heregulin, a cytokine secreted by the breast stromal cells, can activate HER2 by inducing or stabilizing heterodimers with other HER receptors ... growth of breastcancer cells, to trigger the apoptotic signaling inbreast cancers, thus switching the estrogenic hormones from potential mitogens to apoptosis inducers inbreast cancers (Shi, ... activity in treatment of breast cancers in a phase I trial, and conferred therapeutic benefits in combination with chemotherapy in triple-negative breast cancers without an increase in normal...
... understand a population’s health status [22] There is a growing interest in the possible role of exercise in enhancing QOL, reducing recurrence and other diseases, and extending survival incancer ... SL Moderate exercise training and natural killer cell cytotoxic activity inbreastcancer patients Int J Sports Med 1995;16:334-7 Stoll BA Diet and exercise regimens to improve breast carcinoma ... prognosis Cancer 1996;78:2465-70 Courneya KS Exercise interventions during cancer treatment: biopsychosocial outcomes Exerc Sport Sci Rev 2001;29:60-4 McTiernan A Physical activity after cancer: physiologic...
... invasion begins with inflammation around cancer cells Thus, it has been reported that serum CRP levels are higher in cases of invasive cancer than in cases of non-invasive cancer [8,9] The principal ... TNM staging system of breastcancer thus indirectly correlating with the prognosis of the patient CRP estimation does not seem to be very useful in evaluating the patient with breast cancer, though ... Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G: Serum levels of interleukin as a prognostic factor in advanced nonsmall cell lung cancer Oncol Rep 1998, 5:649-652 Erlinger TP, Platz EA,...
... penetrating into the gastric lumen and pericolic soft tissue Other gastrointestinal tumors may also contain calcification At least three types of calcification have been reported in gastric cancer: ... Spurt bleeding from a calcificated gastrointestinal stromal tumor in the stomach J Nippon Med Sch 2005, 72(5):304-307 Balestreri L, Canzonieri V, Morassut S: Calcified gastric cancer CT findings before ... Liegl-Atzwanger B, Fletcher JA, Fletcher CD: Gastrointestinal stromal tumors Virchows Arch 2010, 456(2):111-127 Miettinen M, Lasota J: Gastrointestinal stromal tumors–definition, clinical, histological,...
... not increase local recurrence rate inbreastcancer patients BreastCancer Res Treat 2006, 97:9-15 Peters-Engl C, Konstantiniuk P, Tausch C, Haid A, Hoffmann B, JagoutzHerzlinger M, Kugler F, ... characteristics Sentinel lymph nodes were sectioned at 0.2 cm intervals, and examinations were based on frozen sections in most cases Whether or not metastasis was present was determined intraoperatively ... survival in invasive breast cancers [24] In conclusion, we found that the incidence of sentinel lymph node metastasis in cases of pure DCIS was 0.39% This incidence was lower than that in IDC-predominant...
... Thun MJ: Cancer statistics, 2005 CA Cancer J Clin 2005, 55(1):10-30 American Cancer Society: Cancer Facts & Figures 2004 Atlanta, GA, American Cancer Society; 2004 Cady B, Stone MD, Schuler JG, ... Lichter A, Lippman M, Danforth D, Swain S, Cowan K, deMoss E, MacDonald H, Steinberg S, d'Angelo T, et al.: Results of the National Cancer Institute early breastcancer trial J Natl Cancer Inst ... Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K: Postoperative radiotherapy in high-risk premenopausal women with breastcancer who receive adjuvant chemotherapy Danish Breast Cancer...
... in tissue fixation and processing, variable sensitivity and specificity of commercially available antibodies, and differences in scoring criteria with considerable interobserver variability in ... fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breastcancer tissues Clin BreastCancer 2004, 5(1):63-9 Dybdal N, Leiberman G, Anderson S: Determination ... Traditional Chinese Medicine Hospital which are the two main hospitals for the treatment of breastcancerin Guilin city of China The specimens were fixed in 10% neutral-buffered formalin (pH7.4) for 24...
... Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN: Risk of pneumonitis inbreastcancer patients treated with radiation therapy and combination chemotherapy with paclitaxel J Natl Cancer Inst ... instrument for use in international clinical trials in oncology J Natl Cancer Inst 1993, 85:365-376 21 Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams ... symptomatic RP was rare in this study when 3-D treatment planning, aiming at minimizing V20 to the ipsilateral lung to